IN THE CLAIMS:

Claims 1-88 (Canceled).

89. (Previously Presented) An expandable intraluminal graft for use within a body passageway including a body member, a intermediate compound, and biological agent, said intermediate compound, said at least one biological agent, and mixtures thereof coated on at least a portion of the body member, said body member having first and second ends and a wall surface disposed between said first and second ends defining a longitudinal axis of said body member, said body member having a first cross-sectional shape having a first cross-sectional area which permits intraluminal delivery of said body member into the body cavity, and a second expanded cross-sectional shape having a second cross-sectional area which is greater than said first cross-sectional area, said biological agent at least partially coated on or secured to the surface of said body member, said biological agent including a compound selected from the group consisting of Trapidil, GM-CSF, Taxol, rapamycin, and mixtures thereof, said biological agent including at least one of Trapidil, GM-CSF, and mixtures thereof, said intermediate compound at least partially securing said biological agent to said body member, said intermediate compound at least partially encapsulating said biological agent in said intermediate compound, and combinations thereof.

90. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said intermediate compound is at least partially formed of a biodegradable and forms a polymer salt complex with said biological agent.

91. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said intermediate compound includes a plurality of radiation induced cross-links that at least partially encapsulate said biological agent in said intermediate compound.

92. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said biological agent includes Trapidil and a second compound selected from the group consisting of GM-CSF, Taxol, rapamycin, and mixtures thereof.

93. (Previously Presented) The expandable intraluminal graft as defined in claim 90, wherein said biological agent includes Trapidil and a second compound selected from the group consisting of GM-CSF, Taxol, rapamycin, and mixtures thereof.

94. (Previously Presented) The expandable intraluminal graft as defined in claim 91, wherein said biological agent includes Trapidil and a second compound selected from the group consisting of GM-CSF, Taxol, rapamycin, and mixtures thereof.

95. (Previously Presented) The expandable intraluminal graft as defined in claim 92, wherein said biological agent includes Trapidil and GM-CSF.

96. (Previously Presented) The expandable intraluminal graft as defined in claim 93, wherein said biological agent includes Trapidil and GM-CSF.

97. (Previously Presented) The expandable intraluminal graft as defined in claim 94, wherein said biological agent includes Trapidil and GM-CSF.

98. (Previously Presented) The expandable intraluminal graft as defined in claim 92, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

99. (Previously Presented) The expandable intraluminal graft as defined in claim 95, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

100. (Previously Presented) The expandable intraluminal graft as defined in claim 93, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

101. (Previously Presented) The expandable intraluminal graft as defined in claim 96, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

102. (Previously Presented) The expandable intraluminal graft as defined in claim 94, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

103. (Previously Presented) The expandable intraluminal graft as defined in claim 97, wherein said biological agent includes Taxol, rapamycin, and mixtures thereof.

104. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said biological agent is releasably coated on said stent.

105. (Previously Presented) The expandable intraluminal graft as defined in claim 92, wherein said biological agent is releasably coated on said stent.

106. (Previously Presented) The expandable intraluminal graft as defined in claim 98, wherein said biological agent is releasably coated on said stent.

107. (Previously Presented) The expandable intraluminal graft as defined in claim 99, wherein said biological agent is releasably coated on said stent.

108. (Previously Presented) The expandable intraluminal graft as defined in claim 100, wherein said biological agent is releasably coated on said stent.

109. (Previously Presented) The expandable intraluminal graft as defined in claim 101, wherein said biological agent is releasably coated on said stent.

110. (Previously Presented) The expandable intraluminal graft as defined in claim 102, wherein said biological agent is releasably coated on said stent.

111. (Previously Presented) The expandable intraluminal graft as defined in claim 103, wherein said biological agent is releasably coated on said stent.

112. (Previously Presented) The expandable intraluminal graft as defined in claim 91, wherein said cross-linking in said intermediate compound at least partially delays delivery of said biological agent into said body passageway.

113. (Previously Presented) The expandable intraluminal graft as defined in claim 110, wherein said cross-linking in said intermediate compound at least partially delays delivery of said biological agent into said body passageway.

114. (Previously Presented) The expandable intraluminal graft as defined in claim 111, wherein said cross-linking in said intermediate compound at least partially delays delivery of said biological agent into said body passageway.

115. (Previously Presented) The expandable intraluminal graft as defined in claim 90, wherein said intermediate compound includes a polymer, a copolymer or mixtures thereof.

116. (Previously Presented) The expandable intraluminal graft as defined in claim 108, wherein said intermediate compound includes a polymer, a copolymer or mixtures thereof.

117. (Previously Presented) The expandable intraluminal graft as defined in claim 109, wherein said intermediate compound includes a polymer, a copolymer or mixtures thereof.

118. (Previously Presented) The expandable intraluminal graft as defined in claim 115, wherein said intermediate compound includes hydrophobic and hydrophilic compounds.

119. (Previously Presented) The expandable intraluminal graft as defined in claim 116, wherein said intermediate compound includes hydrophobic and hydrophilic compounds.

120. (Previously Presented) The expandable intraluminal graft as defined in claim 117, wherein said intermediate compound includes hydrophobic and hydrophilic compounds.

121. (Previously Presented) The expandable intraluminal graft as defined in claim 118, wherein said intermediate compound includes an ethylene-acrylic acid copolymer.

122. (Previously Presented) The expandable intraluminal graft as defined in claim 119, wherein said intermediate compound includes an ethylene-acrylic acid copolymer.

123. (Previously Presented) The expandable intraluminal graft as defined in claim 120, wherein said intermediate compound includes an ethylene-acrylic acid copolymer.

124. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said body member maintains a substantially constant longitudinal length when expanded from said first cross-sectional shape to said second cross-sectional shape.

125. (Previously Presented) The expandable intraluminal graft as defined in claim 123, wherein said body member maintains a substantially constant longitudinal length when expanded from said first cross-sectional shape to said second cross-sectional shape.

126. (Previously Presented) The expandable intraluminal graft as defined in claim 114, wherein said body member maintains a substantially constant longitudinal length when expanded from said first cross-sectional shape to said second cross-sectional shape.

127. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said first and second ends having a substantially smooth surface.

128. (Previously Presented) The expandable intraluminal graft as defined in claim 125, wherein said first and second ends having a substantially smooth surface.

129. (Previously Presented) The expandable intraluminal graft as defined in claim 126, wherein said first and second ends having a substantially smooth surface.

130. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said body member is at least partially coated with a material that is visible under fluoroscopy, said material being coated on an outer surface of said body member and at least one end of said body member.

131. (Previously Presented) The expandable intraluminal graft as defined in claim 131, wherein said body member is at least partially coated with a material that is visible under fluoroscopy, said material being coated on an outer surface of said body member and at least one end of said body member.

132. (Previously Presented) The expandable intraluminal graft as defined in claim 129, wherein said body member is at least partially coated with a material that is visible under fluoroscopy, said material being coated on an outer surface of said body member and at least one end of said body member.

133. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein said body member is treated with Gamma or Beta radiation to reduce the vascular narrowing of at least a portion of said body cavity.

134. (Previously Presented) The expandable intraluminal graft as defined in claim 131, wherein said body member is treated with Gamma or Beta radiation to reduce the vascular narrowing of at least a portion of said body cavity.

135. (Previously Presented) The expandable intraluminal graft as defined in claim 132, wherein said body member is treated with Gamma or Beta radiation to reduce the vascular narrowing of at least a portion of said body cavity.

136. (Withdrawn) The expandable intraluminal graft as defined in claim 89, including a balloon, said balloon including at least one opening to allow delivery of said biological substance from an interior of said balloon to said body cavity, said biological substance includes at least one of said biological agents.

137. (Withdrawn) The expandable intraluminal graft as defined in claim 134, including a balloon, said balloon including at least one opening to allow delivery of said biological substance from an interior of said balloon to said body cavity, said biological substance includes at least one of said biological agents.

138. (Withdrawn) The expandable intraluminal graft as defined in claim 135, including a balloon, said balloon including at least one opening to allow delivery of said biological substance from an interior of said balloon to said body cavity, said biological substance includes at least one of said biological agents.

139. (Previously Presented) The expandable intraluminal graft as defined in claim 89, wherein at least a portion of said body member is formed of a biodegradable material.

140. (Previously Presented) The expandable intraluminal graft as defined in claim 134, wherein at least a portion of said body member is formed of a biodegradable material.

141. (Previously Presented) The expandable intraluminal graft as defined in claim 135, wherein at least a portion of said body member is formed of a biodegradable material.